ALZ-NET collects clinical and safety data about patients being evaluated for memory concerns or receiving new FDA-approved treatments for Alzheimer’s disease, including drugs/medications and devices, and tracks the long-term health outcomes associated with their use in real-world settings. ALZ-NET is a voluntary health care provider-enrolled patient network.

Voluntary provider-enrolled patient registry that collects information on treatments for Alzheimer’s Disease from patient’s being evaluated for or treated with novel FDA-approved Alzheimer’s therapies such as Lecanemab.

---

Inclusion Criteria

Qualified individuals are defined by those who are:

• Being evaluated for treatment with Lecanemab
• will be initiating treatment with Lecanemab or have already initiated treatment with Lecanemab